亚洲日韩欧美综合-亚洲日韩欧美一区二区在线-亚洲日韩欧美视频-亚洲日韩精品欧美一区二区-国产欧美日韩综合

會員登錄|免費注冊|忘記密碼|管理入口 返回主站||保存桌面|手機瀏覽|聯(lián)系方式|購物車
企業(yè)會員第1年

湖南韻邦生物醫(yī)藥有限公司  

生化試劑

搜索
新聞中心
  • 暫無新聞
產(chǎn)品分類
  • 暫無分類
聯(lián)系方式
  • 聯(lián)系人:肖小姐
  • 電話:0731-85529965
  • 郵件:ivy@hnhbsj.com
  • QQ:3002708854
站內(nèi)搜索
 
榮譽資質(zhì)
  • 暫未上傳
友情鏈接
  • 暫無鏈接
首頁 > 供應(yīng)產(chǎn)品 > 26239-55-4 ADA 韻邦生產(chǎn) 匯百試劑
26239-55-4 ADA 韻邦生產(chǎn) 匯百試劑
單價 面議對比
詢價 暫無
發(fā)貨 湖南長沙市付款后3天內(nèi)
品牌 匯百試劑
過期 長期有效
更新 2021-08-13 15:18
 
詳細信息
中文名稱:N-(2-乙酰氨基)亞氨基二乙酸
CAS號:26239-55-4
中文別名: N-(2-乙酰胺基)-2-亞氨基二乙酸; 乙酰氨氨基二乙酸
英文名稱:2,2'-((2-Amino-2-oxoethyl)azanediyl)diacetic acid
英文別名: ADA; N-(2-Acetamido)iminodiacetic acid; N-(Carbamoylmethyl)iminodiacetic acid; N-(2-Amino-2-oxoethyl)-N-(carboxymethyl)-glycine;
EINEC:247-530-0
分子式:C6H10N2O5
分子量:190.154
©2025 湖南韻邦生物醫(yī)藥有限公司 版權(quán)所有   技術(shù)支持:化工網(wǎng)   訪問量:13110  
 
主站蜘蛛池模板: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |